Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

BUY
$0.21 - $0.35 $96 - $161
460 Added 793.1%
518 $0
Q4 2022

Feb 14, 2023

SELL
$0.22 - $8.4 $2,692 - $102,807
-12,239 Reduced 99.53%
58 $0
Q3 2022

Nov 14, 2022

SELL
$0.41 - $8.8 $20,988 - $450,489
-51,192 Reduced 80.63%
12,297 $5,000
Q2 2022

Aug 15, 2022

SELL
$0.42 - $0.65 $423,395 - $655,254
-1,008,084 Reduced 94.08%
63,489 $38,000
Q1 2022

May 16, 2022

BUY
$0.54 - $2.74 $17,486 - $88,726
32,382 Added 3.12%
1,071,573 $646,000
Q4 2021

Feb 14, 2022

SELL
$2.33 - $3.37 $87,128 - $126,017
-37,394 Reduced 3.47%
1,039,191 $2.77 Million
Q3 2021

Nov 15, 2021

SELL
$2.52 - $2.99 $1.51 Million - $1.79 Million
-598,825 Reduced 35.74%
1,076,585 $2.97 Million
Q2 2021

Aug 16, 2021

SELL
$2.6 - $3.65 $1.73 Million - $2.43 Million
-666,838 Reduced 28.47%
1,675,410 $4.77 Million
Q1 2021

May 17, 2021

SELL
$2.73 - $4.5 $59,770 - $98,523
-21,894 Reduced 0.93%
2,342,248 $8.03 Million
Q4 2020

Feb 16, 2021

SELL
$2.6 - $3.32 $957,395 - $1.22 Million
-368,229 Reduced 13.48%
2,364,142 $6.24 Million
Q3 2020

Nov 16, 2020

SELL
$2.46 - $4.27 $113,359 - $196,765
-46,081 Reduced 1.66%
2,732,371 $8.53 Million
Q2 2020

Aug 14, 2020

BUY
$1.45 - $4.3 $2.5 Million - $7.41 Million
1,723,267 Added 163.31%
2,778,452 $11.5 Million
Q1 2020

May 15, 2020

BUY
$0.75 - $2.55 $746,066 - $2.54 Million
994,755 Added 1646.13%
1,055,185 $1.7 Million
Q2 2019

Aug 14, 2019

BUY
$2.45 - $3.32 $59,588 - $80,749
24,322 Added 67.36%
60,430 $151,000
Q3 2018

Nov 13, 2018

BUY
$3.39 - $4.61 $5,491 - $7,468
1,620 Added 4.7%
36,108 $0
Q2 2018

Aug 10, 2018

BUY
$1.89 - $4.95 $34,433 - $90,184
18,219 Added 111.99%
34,488 $0
Q4 2017

Feb 09, 2018

BUY
$1.91 - $2.83 $31,073 - $46,041
16,269
16,269 $34,000

Others Institutions Holding MEIP

# of Institutions
1
Shares Held
2K
Call Options Held
0
Put Options Held
0

About MEI Pharma, Inc.


  • Ticker MEIP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 133,261,000
  • Market Cap $385M
  • Description
  • MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymp...
More about MEIP
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.